MedTrace Logo

Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)

NCT01625559 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-04-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD

Conditions

  • Stargardt's Macular Dystrophy

Interventions

BIOLOGICAL

MA09-hRPE

MA09-hRPE cells

Sponsors & Collaborators

  • CHABiotech CO., Ltd

    lead INDUSTRY

Principal Investigators

  • Wonkyung Song · CHA Bundang Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01625559 on ClinicalTrials.gov